glp 1 neurotransmitter Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics Further support for GLP-1R agonists

Clinicians should screen for history of pancreatitis, severe gastrointestinal disease (particularly severe gastroparesis), diabetic retinopathy (particularly if intensifying glycemic control rapidly), and gallbladder disease, as these conditions may influence treatment decisions or require closer monitoring

The abdomen, front of the thighs, and back of the upper arms work best for this

The recent research also found that although persistence among the 45 percent of the population using weekly-dosed semaglutide (Ozempic and Wegovy ) was somewhat better, still only 1 in 4 of those initiating semaglutide treatment for obesity remained on GLP-1 therapy at two years

M.HornC

It provides an easy, low-barrier alternative

Benefits of the maintenance approach include sustained appetite regulation, continued metabolic support, fewer side effects at lower doses, and easier dose escalation if weight begins to creep